Summary: A new study identifies dopamine dysfunction as a previously unrecognized driver of memory loss in Alzheimer’s disease. Focusing on the entorhinal cortex—the brain’s gateway to hippocampal memory processing—researchers found dopamine levels drop to under 20% of normal in an Alzheimer’s mouse model, causing memory circuits to fail.
Importantly, restoring dopamine signaling either with optogenetic stimulation or with the Parkinson’s drug Levodopa (L-DOPA) normalized neural activity and fully reversed cognitive deficits in the animal model, pointing to a promising therapeutic direction for memory restoration.
Key Facts
- The Entorhinal Collapse: In a knock-in mouse model of Alzheimer’s disease, dopamine concentrations in the entorhinal cortex fell to less than 20% of normal, producing a near-complete failure of neurons that encode memories to respond to stimuli.
- Associative Memory Failure: This dramatic neurochemical loss directly corresponded with impaired associative memory, shown by the animals’ inability to complete odor-based learning tasks.
- Bypassing the Plaques: Therapies focused on clearing amyloid-β and tau proteins have had limited success in restoring cognition. This approach targets the active circuitry of memory rather than only removing pathological proteins.
- Dual Restoration Pathways: Memory function was rescued by two independent methods: optogenetics—using light to activate specific dopamine fibers—and Levodopa (L-DOPA), a widely available medication that replenishes dopamine.
Source: Tohoku University
Imagine a future in which some patients with Alzheimer’s disease could recover memories once thought lost. It may sound like science fiction, but a collaborative study led by researchers at Tohoku University and the University of California, Irvine identifies early dopamine disruption as a central mechanism of memory impairment and reveals practical ways to reverse that dysfunction.
The full report was published in Nature Neuroscience on April 23, 2026.
Memory formation commonly links sensory experiences—like a scent or a song—to past events. Scientists have long known that the medial temporal lobe, especially the hippocampus and its inputs, is central to forming lasting memories. Yet researchers have struggled to explain which early circuit changes disrupt that process in Alzheimer’s disease.
To address this question, the research team led by Kei Igarashi, Distinguished Professor at Tohoku University School of Medicine, investigated the entorhinal cortex, a critical gateway that conveys information into the hippocampus and is essential for encoding experiences as memory.
Earlier work hinted that dopamine plays a key role in memory formation within this region. The team therefore examined whether dopamine dysfunction might underlie the memory deficits seen in Alzheimer’s disease models.
In a genetically engineered mouse model that mimics aspects of Alzheimer’s pathology, dopamine levels in the lateral entorhinal cortex were dramatically reduced—below 20% of normal. This decline correlated with pronounced associative memory impairments during behavioral tests that relied on scent-based learning. Electrophysiological recordings showed that neurons in entorhinal cortical layers 2 and 3, which normally encode associations, failed to fire reliably when presented with stimuli to be encoded as memories.
Next, the investigators tested whether restoring dopamine could revive memory circuits. Using optogenetics to selectively activate dopamine-carrying fibers projecting to the entorhinal cortex, they were able to rescue associative learning behavior in the mice. Equally notable, systemic treatment with Levodopa (L-DOPA), a clinically available dopamine precursor commonly used to treat Parkinson’s disease, restored normal neural encoding in the entorhinal cortex and improved memory performance on behavioral tasks.
“We revealed that dopamine dysfunction plays a central role in memory impairment in Alzheimer’s disease,” said Kei Igarashi. “This unexpected finding opens new possibilities for therapeutic intervention for the millions affected worldwide.”
Unlike strategies that focus primarily on clearing amyloid-β or tau aggregates, these results highlight the importance of directly addressing circuit dysfunction. Restoring dopamine signaling within the entorhinal cortex appears capable of rebooting the neural machinery required for associative memory encoding, which may complement or extend the benefits of protein-targeting therapies.
Dopamine-based therapies—whether targeted neuromodulation or pharmacological approaches—could represent a promising new direction in Alzheimer’s research, with the potential to slow or even reverse cognitive decline when delivered at appropriate stages of disease.
Key Questions Answered:
A: Parkinson’s symptoms arise from dopamine loss in motor-control systems, which is why Levodopa replenishes dopamine. This study shows a similar but previously underappreciated loss of dopamine in memory-related regions—the entorhinal cortex—reducing levels to under 20%. By restoring dopamine, Levodopa reactivates the starved memory circuits, normalizes neural firing patterns, and improves cognitive performance in the animal model.
A: The entorhinal cortex functions as the main interface between sensory and cortical information and the hippocampus, the brain’s core memory-forming structure. When entorhinal neurons do not receive adequate dopamine, they fail to fire correctly and cannot pass experiences on to the hippocampus for consolidation into long-term memories.
A: The study demonstrates a major conceptual advance in animal models: early dopamine dysfunction can cause memory impairment, and restoring dopamine can reverse those deficits. While these findings are promising, they come from preclinical work. Clinical studies will be needed to determine safety, timing, dosage, and efficacy in people with Alzheimer’s disease.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was added by staff to clarify implications and next steps.
About this Alzheimer’s disease and neuropharmacology research news
Author: Public Relations Office, Tohoku University
Source: Tohoku University
Contact: Public Relations Office – Tohoku University
Image: The image is credited to Neuroscience News
Original Research: Open access. “Early dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer’s disease” by Tatsuki Nakagawa et al., Nature Neuroscience. DOI: 10.1038/s41593-026-02260-w
Abstract
Early dopamine disruption in the entorhinal cortex of a knock-in model of Alzheimer’s disease
The entorhinal cortex is a critical area for memory formation and one of the earliest regions to show histological and functional changes in Alzheimer’s disease (AD). Its selective vulnerability and the circuit mechanisms behind it have been unclear.
This study demonstrates that dopamine neurons projecting to the lateral entorhinal cortex (LEC)—a region essential for memory in healthy brains—become dysfunctional at an early pathological stage in an amyloid precursor protein knock-in model, producing associative memory impairments.
Dopamine dysfunction disrupted associative memory encoding in LEC layers 2/3. Optogenetic reactivation of dopamine fibers in the LEC rescued associative learning, and systemic L-DOPA treatment restored both neuronal encoding in the LEC and associative memory performance in the model.
These findings suggest that early dysfunction of LEC-projecting dopamine neurons contributes to memory impairment in AD and support the clinical investigation of LEC dopamine signaling in patients with Alzheimer’s disease.